Ohio Reports Growing Cases of Gonorrhea Not Responding to Commonly Used Antibiotics

Article

In a sign of the growing global problem of drug resistance, researchers from Ohio reported a steady increase in the percentages of cases of gonorrhea that did not respond to the usual antibiotics.

Southern Ohio has been hit with an outbreak of drug-resistant gonorrhea, investigators reported today at IDWeek 2016 in New Orleans, LA.

Thomas Herchline, MD, of Wright State University Boonshoft School of Medicine in Dayton, OH and Peter Greene, a public health intern in the Dayton & Montgomery County Office of the Health Commissioner are due to present their findings Saturday Oct. 29.

In a late-breaking abstract, the team wrote that there were no drug resistant isolates of gonorrhea in 1996, but that as of July 31, 2016, of 51 isolates tested, 15.7% were resistant to ciprofloxacin, and 5.9% were resistant to azithromycin. No isolates tested from 2011 to 2016 showed reduced susceptibility to ceftriaxone, however.

Commenting on the study at a news briefing Oct. 26, ID Week officials said the report showed drug resistance is a growing problem due to overuse of antibiotics.

Resistant strains that did not respond to fluoroquinolones (FQ) originated in the 1980s and subsequently spread throughout the continental US.

Based on that growing resistance, the US Centers for Disease Control and Prevention (CDC) updated treatment guidelines to no longer include as first-line therapy. The CDC also recommended monitoring local resistance patterns.

The Dayton health department has been doing that, the team said.

“There has been a rapid emergency of CIP and AMS resistance,” they wrote about their findings, “These results demonstrate that local susceptibility testing provides important information for clinical decision-making.”

Related Coverage:

Antibiotic Resistance a Harsh Reality for Gonorrhea Patients

The STD Epidemic Is Getting Worse in the US

Related Videos
Evaluating MM120 for GAD with Daniel Karlin, MD, and Reid Robinson, MD, MBA
Daniel Su, MD: | Image Credit: Retina Vitreous-Associates Medical Group
The Future of DSM-5-TR with APA Members Nitin Gogtay, Maria Oquendo, Jonathan Alpert
Ashkan Abbey, MD: 3-Year Efficacy of Pegcetacoplan for Geographic Atrophy | Image Credit: Texas Retina AssociatesImage Credit:
Clozapine and Second-Generation Antipsychotics for Schizophrenia, with John Kane, MD
Roger S. McIntyre, MD: GLP-1 Agonists for Psychiatry?
John Kane, MD: Shifts in Antipsychotics for Schizophrenia
© 2024 MJH Life Sciences

All rights reserved.